If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.58    -0.025 (-1.52%)
Bid:
1.32
Ask:
1.93
Spread: 0.61 (46.212%)
Market Cap: £5.54m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Holding(s) in Company

26 Feb 2009 09:00

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: Notifications of Major Interests in Shares 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Proteome Sciences plc 2. Reason for notification [Yes/No] An acquisition or disposal of voting rights Yes An acquisition or disposal of financial instruments which No may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights No Other (please specify): No

3. Full name of person(s) subject to Sanofi-Aventis Deutschland GmbH notification

obligation: 4. Full name of shareholder(s) (if different from 3): 5. Date of transaction (and date on 24 February 2009 which the threshold is crossed or reached if different): 6. Date on which issuer notified: 25 February 2009 7. Threshold(s) that is/are crossed or 9.00% reached: 8: Notified Details A: Voting rights attached to shares Class/type of Situation previous to Resulting situation after shares the triggering the triggering transaction transaction If possible Number of Number of Number of Number of Percentage of use shares voting shares voting rights voting rights ISIN code rights Direct Indirect Direct Indirect GB003104196 13,663,380 13,663,380 12,286,187 12,286,187 9.25% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ No. of voting Percentage of financial date conversion rights that may be voting rights instrument period/date acquired (if the instrument exercised/ converted) Total (A+B) Number of voting rights Percentage of voting rights 12,286,187 9.25%

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable:

Proxy Voting: 10. Name of proxy holder: 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: 14 Contact name: James Malthouse 15. Contact telephone name: +44 1932 865065

vendor
Date   Source Headline
22nd Jun 20267:00 amRNSTarget engagement/chemoproteomics contract
1st Jun 20267:00 amRNSDirectorate Changes
14th May 202612:55 pmRNSResult of AGM
14th May 202612:00 pmRNSAnnual General Meeting Statement
15th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
4th Feb 202611:08 amRNSHolding(s) in Company
3rd Feb 202612:43 pmRNSHolding(s) in Company
28th Jan 20263:31 pmRNSResult of Oversubscribed Retail Offer
26th Jan 20267:05 amRNSRetail Offer to raise up to £60,000
26th Jan 20267:00 amRNS£840,000 Fundraise and Retail Offer
6th Jan 20267:00 amRNSTwo Further Substantial Contracts for PRM
8th Dec 20257:00 amRNSSubstantial contract for Proteome Sciences
25th Nov 20257:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20257:00 amRNSInterim Results
16th May 20251:17 pmRNSResult of AGM
16th May 202512:00 pmRNSAGM Statement
10th Apr 20257:00 amRNSFinal Results
4th Apr 20251:00 pmRNSNotice of Results and Investor Presentation
21st Feb 20257:00 amRNSContract Win
23rd Dec 20247:08 amRNSLoan Facility, Trading Update & Directorate Change
13th Sep 20247:00 amRNSInterim Results and Directorate Change
16th May 20241:10 pmRNSResult of AGM
16th May 20247:00 amRNSAGM Statement
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.